Avenue Biosciences utilizes a machine learning-powered protein engineering platform to optimize protein production systems. This technology analyzes thousands of signal peptides to significantly enhance protein yield and quality for biotherapeutics and biotechnology tools. The platform is especially effective for improving the expression of difficult-to-produce mammalian proteins.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
- VC website (opens in a new tab)
- Startup funding source · Source unavailable
Founders
Product
Problem
Producing certain therapeutic proteins and biologics at high yields can be challenging, hindering the development of mRNA therapies, vaccines, and other protein-based drugs. Traditional protein expression methods often struggle with difficult-to-express proteins, leading to bottlenecks in research and manufacturing.
Solution
Avenue Biosciences offers a protein engineering platform that leverages high-throughput chemistry and machine learning to optimize protein expression. The platform analyzes thousands of N-terminal signal peptides to identify candidates that significantly improve protein yield, in some cases by up to 500%. This technology is compatible with various mammalian protein production systems, including mRNA therapies, synthetic proteins, and multi-chain proteins like monoclonal antibodies. By enhancing protein production, Avenue Biosciences aims to accelerate therapeutic development and reduce time-to-market for novel biologics.
Target Audience
The primary target audience includes biopharmaceutical companies, biotechnology firms, and research institutions involved in developing protein biologics, mRNA therapies, vaccines, and other protein-based therapeutics.
Features
- High-throughput screening of naturally occurring and genetically engineered signal peptides
- Machine learning-driven analysis to predict and optimize protein expression
- Demonstrated yield improvements of up to 500% in external validations
- Compatible with diverse protein production systems, including mammalian cell lines
- Enables production of difficult-to-express proteins that hinder therapeutic development
- Facilitates single-chain and multi-chain protein expression optimization